131I–Tositumomab in Lymphoma
نویسندگان
چکیده
منابع مشابه
NON-HODGKIN\'S LYMPHOMA IN IRAN
Two hundred and ninety cases of non-Hodgkin's lymphoma from the Fars Province Cancer Registry and Mashad University Hospital were reviewed and classified according to the new International Working Formulation for clinical use. The cases fall into low-grade (35 male, 26 female), intermediate-grade (61 male, 26 female), and high-grade (84 male, 26 female) groups. Each group includes several ...
متن کاملNon-Hodgkin Lymphoma (NHL) in Pakistan
Lymphomas are classified as Hodgkin’s and Non-Hodgkin’s lymphomas (HL NHL) NHL being further sub-divided into B, T and Null cell categories on the basis of WHO classification. With a few exceptions worldwide, B-NHL are more common, accounting approximately 80-85% of all cases of NHL compared to T-NHL, which accounts for about 10-15% of all NHL cases. The incidence of NHL has shown a steady incr...
متن کاملHodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma
Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...
متن کاملExpression of Anaplastic Lymphoma Kinase Protein in Human Breast Cancer
Background & Objectives: Anaplastic lymphoma Kinase (ALK) is a receptor tyrosine kinase involved in the genesis of several human cancers. ALK was initially identified because of its involvement in anaplastic large cell lymphoma (ALCL). ALK is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops. Studies reveal that the presence of anti-ALK antibodies ...
متن کاملTreatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2009
ISSN: 1718-7729
DOI: 10.3747/co.v16i5.385